S100A9 and primary cutaneous T-cell non-Hodgkin lymphoma: Du et al. (2022) identified that upregulated S100A9 increased CTCL tumor growth via the NF-kB pathway, and then demonstrated that tasquinimod inhibited CTCL tumor growth in vitro by blocking S100A9 and TLR4 [43].